Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Bevacizumab

Bevacizumab Am J Cancer 2004; 3 (3): 195-196 GUEST COMMENTARIES 1175-6357/04/0003-0195/$31.00/0 © 2004 Adis Data Information BV. All rights reserved. Recently reported randomized clinical trial data from patients with metastatic colorectal cancer have provided important safety A Viewpoint by Al B. Benson III information for bevacizumab as a single agent and in combination Robert H. Lurie Comprehensive Cancer Center of with chemotherapy that included both irinotecan and oxaliplatin Northwestern University, Chicago, Illinois, USA combinations. In addition, both fluorouracil (FU)/leucovorin plus Strategies that develop therapies for cancer patients based on bevacizumab and irinotecan/FU/leucovorin plus bevacizumab have shown impressive clinical benefit to date. biologically defined targets represent an important step toward the goal of developing individualized patient treatments linked to There is now convincing evidence that there is a role for specific tumor characteristics. In particular, the study of tumor targeted therapies in the treatment of colorectal cancer. We have angiogenesis has led to an extensive body of research evaluating the foundation on which to construct laboratory-driven clinical such targets as vascular endothelial growth factor (VEGF), which trials including the evaluation of pharmacogenetic predictors of has been shown in preclinical models to stimulate angiogenesis, therapeutic response and/or severe toxicity. Unfortunately, VEGF thus http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Bevacizumab

Abstract

Am J Cancer 2004; 3 (3): 195-196 GUEST COMMENTARIES 1175-6357/04/0003-0195/$31.00/0 © 2004 Adis Data Information BV. All rights reserved. Recently reported randomized clinical trial data from patients with metastatic colorectal cancer have provided important safety A Viewpoint by Al B. Benson III information for bevacizumab as a single agent and in combination Robert H. Lurie Comprehensive Cancer Center of with chemotherapy that included both irinotecan and oxaliplatin Northwestern...
Loading next page...
 
/lp/springer-journals/bevacizumab-4zl3yqEYc6
Publisher
Springer Journals
Copyright
Copyright © 2004 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200403030-00007
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2004; 3 (3): 195-196 GUEST COMMENTARIES 1175-6357/04/0003-0195/$31.00/0 © 2004 Adis Data Information BV. All rights reserved. Recently reported randomized clinical trial data from patients with metastatic colorectal cancer have provided important safety A Viewpoint by Al B. Benson III information for bevacizumab as a single agent and in combination Robert H. Lurie Comprehensive Cancer Center of with chemotherapy that included both irinotecan and oxaliplatin Northwestern University, Chicago, Illinois, USA combinations. In addition, both fluorouracil (FU)/leucovorin plus Strategies that develop therapies for cancer patients based on bevacizumab and irinotecan/FU/leucovorin plus bevacizumab have shown impressive clinical benefit to date. biologically defined targets represent an important step toward the goal of developing individualized patient treatments linked to There is now convincing evidence that there is a role for specific tumor characteristics. In particular, the study of tumor targeted therapies in the treatment of colorectal cancer. We have angiogenesis has led to an extensive body of research evaluating the foundation on which to construct laboratory-driven clinical such targets as vascular endothelial growth factor (VEGF), which trials including the evaluation of pharmacogenetic predictors of has been shown in preclinical models to stimulate angiogenesis, therapeutic response and/or severe toxicity. Unfortunately, VEGF thus

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.